menu

TAG: HUMMINGBIRD DIAGNOSTICS

JÖRG DEBATIN TO CHAIR THE SUPERVISORY BOARD OF HUMMINGBIRD DIAGNOSTICS GMBH International healthcare leader strengthens miRNA experts

HEIDELBERG, BOSTON, October 9, 2018 – Hummingbird Diagnostics GmbH today announced that Prof. Dr. med. Jörg Debatin is appointed Chairman of the Supervisory Board with immediate effect. The former Vice President and Chief Technology Officer of GE Healthcare and CEO of Amedes AG directed the University Hospital Hamburg-Eppendorf for 8 years as its Medical Director and CEO. He started his professional career as a diagnostic radiologist at the University Hospitals of Duke, Stanford and Zürich (Switzerland). In 1999, he was appointed Professor of Diagnostic Radiology at the University of Essen. Debatin has studied medicine at the University of Heidelberg and holds...

READ MORE
BGI, Hummingbird Diagnostics to Develop miRNA Tests for Neurodegenerative Disorders

Dec 06, 2017 | staff reporter NEW YORK (GenomeWeb) – BGI of China and Hummingbird Diagnostics of Germany have signed a memorandum of understanding to collaborate on miRNA-based molecular diagnostic applications using next-generation sequencing technology, in particular in the areas of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Under the agreement, the partners will use Hummingbird’s miRNA database and expertise in sample preparation as well as BGI’s BGISEQ sequencer and analysis pipeline to develop targeted miRNA in vitro diagnostic assays for Alzheimer’s, Parkinson’s, and other diseases. In addition, the firms will collaborate in the areas of wellness, fitness, and...

READ MORE
Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers: miRNA Experts Sign Framework Agreement

HEIDELBERG and SAARBRÜCKEN, November 14, 2017 – Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the validation of miRNA biomarkers in blood samples, allowing for an early detection of common serious diseases including lung cancer, chronic obstructive lung disease (COPD), Alzheimer’s and Parkinson’s. The project partners at Saarland University are the Department of Human Genetics and the Chair of Clinical Bioinformatics. Hummingbird Diagnostics has been maintaining long-standing research collaborations with both...

READ MORE
Hummingbird Diagnostics & Saarland University Cooperate on Cancer Detection

Hummingbird Diagnostics & Saarland University cooperate on the early detection of cancer by liquid biopsy employing miRNA fingerprints Early detection as key for improved outcome The maybe best strategy in the daily fight against cancer – besides preventive actions such as anti-smoking campaigns – is the in-time detection of malignant tumors. There is an undisputed clinical need for minimally or non-invasive diagnostics that facilitate sensitive and specific discovery of cancers. The panel of possible approaches that is currently explored by research groups and companies worldwide includes different molecular diagnostic options, including protein patterns, gene expression profiles, epigenetics or metabolic marker...

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER